5-benzyl-4-[(E)-N-[3,5-bis(trifluoromethyl)anilino]-C-methylcarbonimidoyl]-1,2-oxazole-3-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-benzyl-4-[(E)-N-[3,5-bis(trifluoromethyl)anilino]-C-methylcarbonimidoyl]-1,2-oxazole-3-carboxylic acid
• 化学式: C₂₁H₁₅F₆N₃O₃
• 分子量: 471.4
• InChiKey: JBGQWKQSSOCCDO-IPBVOBEMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• Novel Inhibitors of System Xc-
  申请人：The University of Montana, Missoula, MT

  公开号：US20150368213A1

  公开（公告）日：2015-12-24

  The present invention is directed to novel inhibitors of system X c − , also known as the cystine/glutamate antiporter. The present invention is further directed to methods of treating and detecting cancer that overexpresses system X c − which includes but is not limited to gliomas (including glioblastoma), triple negative breast cancer, and bladder cancer. The present invention is further directed to methods of treating seizures including epileptic seizures.

  本发明涉及新型系统Xc−抑制剂，也称为半胱氨酸/谷氨酸抗转运体。本发明还涉及治疗和检测过度表达系统Xc−的癌症的方法，其中包括但不限于胶质瘤（包括胶质母细胞瘤）、三阴性乳腺癌和膀胱癌。本发明还涉及治疗癫痫发作，包括癫痫发作的方法。
• Compositions and methods for the treatment of neurodegenerative and other diseases
  申请人：Glialogix, Inc.

  公开号：US10398713B2

  公开（公告）日：2019-09-03

  In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.

  在一个实施方案中，本申请公开了用磺胺嘧啶和磺胺嘧啶药物制剂治疗疾病和失调的方法，其中磺胺嘧啶的生物利用度得到了提高。在另一个实施方案中，本申请还提供了用包含磺胺沙拉嗪的组合物治疗神经退行性疾病和失调的给药方案。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASES
  申请人：Glialogix, Inc.

  公开号：EP2950797A2

  公开（公告）日：2015-12-09
• SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USING THE SAME
  申请人：Abu-Izza, Khawla

  公开号：EP3694837A1

  公开（公告）日：2020-08-19
• Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases
  申请人：Glialogix, Inc.

  公开号：US20140221321A1

  公开（公告）日：2014-08-07

  In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.